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ABSTRACT 
 
Objective 
Orexigenic neuropeptide Y (NPY) and dynorphin (DYN) regulate energy homeostasis. Single 
NPY or dynorphin deletion reduces food intake or increases fat loss. Future developments of 
obesity therapeutics involve targeting multiple pathways. We hypothesised that NPY and 
dynorphin regulate energy homeostasis independently, thus double NPY and dynorphin 
ablation would result in greater weight and/or fat loss than the absence of NPY or dynorphin 
alone. 
Design and methods 
We generated single and double NPY and dynorphin knockout mice (NPYΔ, DYNΔ, 
NPYDYNΔ) and compared body weight, adiposity, feeding behaviour, glucose homeostasis 
and brown adipose tissue uncoupling protein-1 (UCP-1) expression to wildtype counterparts. 
Results 
Body weight and adiposity were significantly increased in NPYDYNΔ, but not in NPYΔ or 
DYNΔ. This was not due to increased food intake or altered UCP-1 expression, which were 
not significantly altered in double knockouts. NPYDYNΔ mice demonstrated increased body 
weight loss after a 24-h fast, with no effect on serum glucose levels after glucose injection. 
Conclusions 
Contrary to the predicted phenotype delineated from single knockouts, double NPY and 
dynorphin deletion resulted in heavier mice, with increased adiposity, despite no significant 
changes in food intake or UCP-1 activity. This indicates that combining long-term opioid 
antagonism with blockade of NPY-ergic systems may not produce anti-obesity effects. 
 
1. Introduction 
The recent decision by the US Food and Drug Authority (FDA) to delay approval of the new 
anti-obesity drug, Contrave ( Orexigen, 2011), has once again reignited the debate of whether 
the effectiveness of weight-loss drugs outweighs their side effects. Contrave, developed by 
Orexigen, is a fixed-dose combination of naltrexone, a non-selective opioid receptor 
antagonist, and bupropion, a selective dopamine reuptake inhibitor ( Orexigen, 2011). Due to 
its cardiovascular effects (Orexigen, 2011), the FDA has sought extensive safety data prior to 
its approval as an oral obesity treatment. Overweight and obesity currently affect billions of 
people worldwide, particularly those in developed nations, and are now becoming 
increasingly prevalent in developing countries also (WHO, 2013). As the rates of this 
epidemic are rising alarmingly (WHO, 2013), with lifestyle interventions having low success 
rates (Mann et al., 2007) and surgery being the only effective treatment (Picot et al., 2009), 
albeit with side effects and not being suitable for everyone, the search for an elusive drug 
cure is rife. 
 A large majority of people with a body mass index in the overweight or obese range 
find that maintaining a reduced body weight in the long-term is a large, compounding hurdle 
in the quest for a healthy body weight. Up to 70% of those that lose weight using lifestyle 
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interventions alone regain the weight within 4 years (Sumithran and Proietto, 2013 and Wing 
and Phelan, 2005). This is due – at least in part – to weight loss activating adaptive 
responses that stimulate appetite and reduce energy expenditure, as recently reviewed 
(Sainsbury and Zhang, 2012). These adaptive responses to energy restriction are seemingly 
mediated by numerous hypothalamic peptides (Sainsbury and Zhang, 2010 and Sainsbury 
and Zhang, 2012), notably neuropeptide Y (NPY) (Stephens et al., 1995) and possibly also 
the opioid peptides, dynorphins (Kalra and Kalra, 1996 and Sainsbury et al., 2007), with the 
aforementioned drug, Contrave, utilising opioid receptor antagonism as one of its 
mechanisms of action. 
 Negative energy balance, such as during dieting and other lifestyle-based weight 
loss, leads to decreased circulating leptin levels (Belza et al., 2009) and – at least in rodents 
– subsequently increased hypothalamic NPY expression (Stephens et al., 1995). Increased 
central NPY-ergic tonus has been shown to result in increased appetite (Clark et al., 1984) 
and reduced physical activity (Heilig et al., 1989). These responses are associated with 
significant decreases in total energy expenditure and body temperature (Hwa et al., 1999), 
along with increases in food efficiency and fat accretion (Stanley et al., 1986). These effects 
of NPY contribute to obesity in rodents when leptin action is permanently reduced (Wong et 
al., 2013), and conceivably also contribute to body weight regain in people after lifestyle-
based weight loss interventions (Sainsbury and Zhang, 2010 and Sainsbury and Zhang, 
2012). Therefore, it would follow on that blocking the effects of increased hypothalamic NPY-
ergic tonus, thus blocking these adaptive responses to energy restriction, could increase the 
effectiveness of weight loss interventions. 
 In addition to the NPY system, the three peptide families of the endogenous opioid 
system – endorphins, enkephalins and dynorphins, which preferentially act on mu (µ), delta 
(δ) and kappa (κ) opioid receptors respectively – are implicated in feeding and body weight 
regulation (Cooper, 1980, Grandison and Guidotti, 1977 and Thornhill et al., 1976). Of these 
endogenous opioid systems, κ opioid receptors have been particularly implicated in these 
processes (Arjune and Bodnar, 1990, Hamilton and Bozarth, 1988 and Levine et al., 1990). 
Specific blockade of κ-opioid receptors significantly reduces fasting-induced hyperphagia in 
rats (Lambert et al., 1993), as well as food intake and body weight in obese rodent models 
(Cole et al., 1995 and Jarosz and Metzger, 2002). Further evidence for a role of κ-opioid 
receptors in the regulation of energy balance is the observation that dynorphin knockout mice 
have significantly less white adipose tissue mass and lose more weight during a 24-h fast 
than wildtype mice (Sainsbury et al., 2007). 
 Evidence suggests that endogenous opioids may contribute to the energy-
conserving, appetite promoting effects of negative energy balance, and that they do so via at 
least partially distinct and additive pathways to those activated by NPY (Cooper, 1980, 
Lambert et al., 1993 and Sainsbury et al., 2007). NPY and pre-prodynorphin mRNA and 
protein are co-localised in regions of the hypothalamus involved in energy homeostasis 
regulation, notably the arcuate nucleus (Lin et al., 2006). After a 24-h fast, there are increases 
in immunoreactivity levels of both NPY (in arcuate and paraventricular nuclei) and dynorphin 
(in the overall hypothalamus) (Przewlocki et al., 1983 and Sahu et al., 1988), suggesting 
potentially similar actions. Notably, double intracerebroventricular administration of a NPY 
antibody and κ-opioid receptor antagonist, norbinaltorphimine, resulted in additive inhibition of 
hyperphagia, greater than responses seen in single NPY or κ-opioid receptor system 
disruption (Lambert et al., 1993). This evidence provides support for the possibility that the 
NPY and dynorphin systems function at least partially independently of one another in the 
control of energy homeostasis. 
 Based on these findings of possible independent and hence additive actions of NPY 
and dynorphin in the regulation of energy balance, and with a view towards future 
development of pharmacological obesity treatments that target dual pathways, we 
hypothesised that double ablation of both NPY and dynorphin function would result in greater 
weight and/or fat loss than the absence of either NPY or dynorphin alone. In this work, we 
specifically tested this hypothesis using a double NPY and dynorphin knockout mouse model 
(NPYDYNΔ), with subsequent analysis of body weight, adiposity, food intake, brown 
adipocyte thermogenesis marker expression, as well as blood glucose response to glucose 
injection. 
 
 
2. Methods and procedures 
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2.1. Ethics statement and animal care 
All research and animal care procedures were approved by the Garvan Institute/St Vincent’s 
Hospital Animal Ethics Committee and in agreement with the Australian Code of Practice for 
the Care and Use of Animals for Scientific Purposes. All mice were group housed, unless 
otherwise stated, under conditions of controlled temperature (22 °C) and illumination (12 h 
light–dark cycle, lights on at 7:00 h) with ad libitum access to water and standard chow (8% 
calories from fat, 21% calories from protein, 71% calories from carbohydrates and 
2.6 kcalories g−1; Gordon’s Specialty Stock Feeds, Yanderra, New South Wales, Australia). 
 
2.2. Generation of knockout mice 
All knockout and wildtype (WT) mice were on the same mixed C57BL/6–129/SvJ background. 
Single NPY and dynorphin knockout mice (NPYΔ and DYNΔ) were generated as previously 
published in (Karl et al., 2008) and (Loacker et al., 2007), respectively. Dynorphin knockout 
leads to deletion of the pre-prodynorphin gene, the common precursor of all five dynorphin 
peptides. Generation of double NPYDYN knockout mice (NPYDYNΔ) was accomplished 
through crossing of the single NPY and dynorphin knockout mice lines. 
 
2.3. Body weight monitoring 
After weaning, animals were weighed once a week at the same time of day throughout the 
duration of the experiment. 
 
2.4. Tissue collection 
At 13–14 weeks of age, mice were culled between 13:00 and 17:00 h by cervical dislocation 
followed by decapitation. The interscapular brown adipose tissue (BAT) as well as white 
adipose tissue (WAT) depots (right inguinal, right epididymal or periovarian (gonadal), 
mesenteric and right retroperitoneal) were removed and weighed. The weights of these WAT 
depots were presented individually and also summed together and expressed as total WAT 
weight, expressed in absolute weight as well as normalised as a percent of body weight. BAT 
samples were stored at −80 °C until subsequent analysis as described below. 
 
2.5. Western blotting 
BAT samples taken from male animals were homogenised in RIPA buffer (25 mM TrisNHCl 
pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) supplemented with 
Complete Protease Inhibitor Cocktail Tablets (Complete Mini, Roche Diagnostic, Mannheim, 
Germany). After centrifugation, clear lysates were collected and protein concentrations were 
measured by a microplate spectrophotometer (Spectramax Plus384, Molecular Devices Inc, 
Silicon Valley, California, USA) using a reagent from Biorad (Biorad, Gladesville, New South 
Wales, Australia). Equal amounts of tissue lysates (20 µg protein) were resolved by SDS–
PAGE and immunoblotted with antibodies against uncoupling protein-1 (UCP-1) (Alpha 
Diagnostic International Inc, San Antonio, Texas, USA) and peroxisome proliferator-activated 
receptor-gamma coactivator 1 alpha (PGC1-α) (Calbiochem, Merck Pty Ltd, Kilsyth, Victoria, 
Australia). Immunolabelled bands were then quantified using densitometry. 
 
2.6. Feeding studies 
At 10–11 weeks of age, mice were transferred from group housing with soft bedding to 
individual cages with paper towel bedding and acclimatised to these new conditions for two to 
four nights. Food intake was measured at 11–12 weeks of age both in the fed state 
(spontaneous food intake), as well as in response to 24-h fasting. Spontaneous food intake 
was determined over a 24-h period, and 24-h fasting-induced food intake was measured at 
24, 48 and 72 h after reintroduction of food. Body weight was tracked for the duration of the 
feeding studies. Actual food intake was calculated as the weight of food taken from the 
hopper minus the weight of food spillage in the cage. Mice were placed back onto soft 
bedding after completion of feeding studies. 
 
2.7. Glucose metabolism 
At 12–13 weeks of age, knockout and wildtype mice underwent a glucose tolerance test. 
Briefly, mice were fasted for 16–24 h before intraperitoneal injection between 13:00 and 
15:00 h of a 10% d-glucose solution (1.0 g/kg) (Astra Zeneca, North Ryde, New South Wales, 
Australia). Blood samples were obtained from the tail tip at 0, 15, 30, 60 and 90 min after 
Nguyen	  et	  al.:	  Neuropeptides,	  48(3):	  143-­‐151,	  2014	  	  	  
glucose injection. Serum was stored at −20 °C for subsequent analysis of glucose using a 
glucose oxidase kit (Trace Scientific, Clayton, Victoria, Australia). Integrated areas under the 
resultant glucose response curves (AUC) were calculated (without subtracting baseline 
values) between t = 0 and t = 90 min after glucose injection, and are expressed in arbitrary 
units. 
 
2.8. Statistical analyses 
All data are expressed as means ± SEM. Differences among groups of mice were assessed 
by ANOVA (for BAT weight, total WAT weight, BAT UCP-1 and PGC1-α expression, 
spontaneous food intake, body weight lost after a 24-h fast, area under the curve for plasma 
glucose after intraperitoneal glucose injection) or repeated measures ANOVA (for body 
weight, individual WAT depot weights, 24-h fasting-induced feeding, body weight changes 
over 72 h, serum glucose curves following intraperitoneal glucose injection), with Fisher’s 
post hoc tests where appropriate. Statistical analyses were performed with SPSS for Mac OS 
X version 16.0.1 (SPSS Inc, Chicago, Illinois, USA). Statistical significance was defined as 
P < 0.05. 
 
3. Results 
 
3.1. Body weight is increased after double NPY and dynorphin ablation 
Measuring the body weight of wildtype (WT), NPYΔ, DYNΔ and NPYDYNΔ mice from 5 to 
13 weeks of age revealed that both male and female NPYDYNΔ mice, as well as female 
DYNΔ mice, were significantly heavier than their wildtype counterparts (Fig. 1). Importantly, 
male but not female NPYDYNΔ mice were already heavier than wildtype mice at 5 weeks of 
age (Fig. 1). 
 
 3.2. Increased body weight in NPYDYNΔ mice is due to increased adiposity 
At the conclusion of the experiment at 13–14 weeks of age, individual white adipose tissue 
depots were dissected and weighed to determine the degree of adiposity. Double ablation of 
NPY and dynorphin resulted in increased adiposity in both male and female mice, reflected by 
increased weight of the white adipose tissues, expressed either as absolute weight (Fig. 2A, 
B) or as a percentage of body weight (Fig. 2C, D). In addition to increased white adipose 
tissue mass, absolute and relative brown adipose tissue mass was significantly increased in 
male (Fig. 2A, C), but not female (Fig. 2B, D) NPYDYNΔ mice. In results broadly consistent 
with our previous observation of reduced fat mass in DYNΔ mice (Sainsbury et al., 2007), our 
current cohort of DYNΔ mice also showed reductions in white adipose tissue depot weights 
relative to wildtype values, significantly so in females for the total weight of these depots (Fig. 
2). 
3.3. Increased body weight gain and adiposity seen in NPYDYNΔ mice is not due to 
increased food intake 
To determine whether the significant increases in body weight and adiposity of double 
knockout mice were due to an increase in energy intake, food intake was measured both  
To gain insight into whether NPYDYNDmice may have had altered
thermogenesis, which could help to explain their obese phenotype,
we measured protein levels of these key mediators of thermoregu-
lation in the brown adipose tissue of our male mice. Compared to
wildtype mice, NPYD mice displayed significantly elevated UCP-1
protein levels, whereas DYND and NPYDYND mice showed no sig-
nificant difference (Fig. 5A). No differences were seen in PGC1-a
protein content in brown adipose tissue when comparing any
knockout group with that of wildtype mice (Fig. 5B).
3.6. Double deletion of both NPY and dynorphin has no effect on
glucose metabolism
As determined by intraperitoneal glucose tolerance tests and
the resultant curves of serum glucose concentrations, and as
compared to wildtype controls, double deletion of NPY and dynor-
phin precursors had no effect on glucose metabolism in male or fe-
male mice (Fig. 6). This was despite significant, albeit opposite,
differences in these parameters in single knockout mice. Indeed,
both male and female NPYDmice demonstrated worsened glucose
tolerance relative to wildtype controls, and male but not female
DYND had improved glucose tolerance (Fig. 6).
4. Discussion
The results from this study demonstrate that the simultaneous
ablation of both NPY and dynorphin in mice does not induce great-
er weight or fat losses than changes induced by single deletion of
either NPY or dynorphin. In fact, double deletion of NPY and dynor-
phin resulted in significantly heavier mice, with corresponding and
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Fig. 1. Increased body weight in double NPYDYND mice. Body weight of male (A) and female (B) wildtype (WT), NPYD, DYND and NPYDYND mice were measured weekly.
Plotted values are means ± SEM of over 5 mice per group. ⁄P < 0.05 and ⁄⁄P < 0.01 compared to WT mice.
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Fig. 2. Markedly increased adiposity in NPYDYND mice despite no significant difference in single NPYD or DYND mice. Weight, in grams and normalised to body weight (%
body weight), of dissected white adipose tissue (WAT) and brown adipose tissue (BAT) depots in male (A, C) and female (B, D) wildtype (WT), NPYD, DYND and NPYDYND
mice. Abbreviations: i, right inguinal; g, right gonadal; m, mesenteric; r, right retroperitoneal; total, summed weight of i, g, m and r WAT depots. Plotted values are
means ± SEM of 6 or more mice per group. ⁄⁄⁄P < 0.001 and ⁄⁄⁄⁄P < 0.0001 compared to WT mice.
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under spontaneous (Fig. 3) and fasting-induced conditions (Fig. 4). Under spontaneous 
conditions, there was no significant difference amongst genotypes with respect to food intake, 
except in female NPYΔ mice, which ate significantly more than their wildtype counterparts 
when intake was expressed in absolute terms (Fig. 3B), but not significantly so when 
normalised to body weight (Fig. 3D). In the post-fasting condition, food intake of double 
NPYDYNΔ mice was not significantly different from that of other groups, either when 
expressed as absolute intake or normalised to body weight (Fig. 4A–D). Interestingly, male 
DYNΔ mice ate significantly less than wildtype mice up to 72 h post-fast, when food intake 
was expressed as absolute intake (Fig. 4A), but not when expressed as a percent of body 
weight (Fig. 4C). No such hypophagia was observed in female DYNΔ mice relative to wildtype 
counterparts, consistent with our previous observation of no effect of dynorphin ablation on 
food intake (Sainsbury et al., 2007). 
 
 
  
To gain insight into whether NPYDYNDmice may have had altered
thermogenesis, which could help to explain their obese phenotype,
we measured protein levels of these key mediators of thermoregu-
lation in the brown adipose tissue of our male mice. Compared to
wildtype mice, NPYD mice displayed significantly elevated UCP-1
protein levels, whereas DYND and NPYDYND mice showed no sig-
nificant difference (Fig. 5A). No differences were seen in PGC1-a
protein content in brown adipose tissue when comparing any
knockout group with that of wildtype mice (Fig. 5B).
3.6. Double deletion of both NPY and dynorphin has no effect on
glucose metabolism
As determined by intraperitoneal glucose tolerance tests and
the resultant curves of serum glucose concentrations, and as
compared to wildtype controls, double deletion of NPY and dynor-
phin precursors had no effect on glucose metabolism in male or fe-
male mice (Fig. 6). This was despite significant, albeit opposite,
differences in these parameters in single knockout mice. Indeed,
both male and female NPYDmice demonstrated worsened glucose
tolerance relative to wildtype controls, and male but not female
DYND had improved glucose tolerance (Fig. 6).
4. Discussion
The results from this study demonstrate that the simultaneous
ablation of both NPY and dynorphin in mice does not induce great-
er weight or fat losses than changes induced by single deletion of
either NPY or dynorphin. In fact, double deletion of NPY and dynor-
phin resulted in significantly heavier mice, with corresponding and
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Fig. 2. Markedly increased adiposity in NPYDYND mice despite no significant difference in single NPYD or DYND mice. Weight, in grams and normalised to body weight (%
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marked increases in adiposity relative to wildtype controls. This
was a surprising finding as it has previously been reported, and
corroborated, although not significantly in both sexes in this par-
ticular study cohort, that DYND mice actually display an antiobe-
sity effect through decreased visceral and subcutaneous adiposity
levels (Sainsbury et al., 2007). Moreover, NPY knockout mice have
previously been shown to exhibit either unchanged food intake
(Erickson et al., 1996a; Hill and Levine, 2003), as well as unaltered
body weight and/or adiposity levels (Erickson et al., 1996a; Zengin
et al., 2013), or in some circumstances, including leptin deficiency
(Erickson et al., 1996b), reductions in fat mass (Baldock et al., 2009;
Zengin et al., 2013). Indeed, in our current cohort of NPY knockout
mice we observed no significant change from wildtype with re-
spect to body weight or adiposity. Therefore, it can be seen that
the obesity-resistant phenotype of single DYNDmice and the unal-
tered body weight and adiposity of NPYD mice in this study was
not carried over to the double NPYDYND mice, which displayed
no combinatory or synergistic effect with regards to body weight
and composition.
The increased body weight and adiposity seen in our NPYDYND
mice cannot be explained by consistent increases in energy intake
in both sexes, and do not seem to be explained by altered thermo-
genesis, either. NPYDYND mice did not have a clearly altered food
intake phenotype, when measured either under spontaneous or
fasting-induced conditions, nor did they exhibit differences from
wildtype mice with respect to brown adipose tissue content of
the major thermogenesis markers, UCP-1 and PGC1-a. Although
the weight of brown adipose tissue in male NPYDYND mice was
significantly increased relative to wildtype, this is likely due to
an increase in the relative size of the brown adipocytes or in-
creased white adipocyte infiltration, as opposed to functional
changes in thermogenic capacity. Therefore, the markedly obese
phenotype of the NPYDYND mice must be due to other factors be-
sides altered energy intake or thermogenesis, such as decreases in
physical activity or energy expenditure, greater propensities to uti-
lise carbohydrates over fats as fuel, or by the increased absorption
of energy from food by the gastrointestinal tract, as has recently
been reported in antibiotic-exposed mice that became obese de-
spite no changes in food intake or energy expenditure (Cho et al.,
2012). Additionally, other changes in body composition have been
demonstrated in these experimental mouse models. Bone tissue
makes a substantial contribution to body weight, and in both single
NPYD and DYND mouse models, indices of elevated cancellous
bone mass have been reported (Baldock et al., 2012). Interestingly,
NPYDYND double knockout mice also exhibit a similar increase in
bone volume to that of single deletion mouse models (Baldock
et al., 2012). This demonstrates a relationship between dynorphin
and NPY in the control of other body composition components be-
sides adipose tissue, namely, bone.
The greater amount of weight lost after a 24-h fast seen in the
female double NPYDYNDmice, which was not seen in either single
NPYD or DYNDmice, could perhaps suggest a synergistic relation-
ship between the two orexigenic pathways of NPY and dynorphin.
Specifically, an additive regulatory mechanism in protecting
against excess loss of body weight after food deprivation may be
a specific function of these two orexigenic pathways, in which
other regulatory pathways are not able to compensate for. Simi-
larly, with regards to glucose homeostasis, additive effects of both
the single NPY and dynorphin ablation appear to occur in the NPY-
DYND mice. Double NPYDYND mice of either gender do not dis-
play an altered blood glucose time-course profile after an
injection of glucose, compared to that of wildtype mice. However,
both male and female NPYDmice demonstrated worsened glucose
tolerance, and male but not female DYND had improved glucose
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Fig. 3. Spontaneous food intake is unchanged by double NPYDYN deletion. Spontaneous 24-h food intake in male (A, C) and female (B, D) wildtype (WT), NPYD, DYND and
NPYDYND mice, expressed in absolute weight (A, B) and normalised to body weight (% body weight, C, D). Plotted values are means ± SEM of 7 or more mice per group.
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3.4. Deletion of NPY, dynorphin, or both neuropeptide precursors results in increased body 
weight loss after a 24-h fast 
Directly following the 24-h fasting period, male but not female NPYΔ and DYNΔ, along with 
female but not male NPYDYNΔ mice lost a significantly greater amount of body weight than 
their wildtype counterparts (Fig. 4E–H). Weight regain during the 72-h post-fasting period was 
similar between NPYDYNΔ and wildtype mice of both sexes, but male NPYΔ showed a 
significantly delayed regain and female DYNΔ showed a significantly faster regain relative to 
wildtype mice (Fig. 4I, J). 
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3.5. Obese NPYDYNΔ mice do not display reductions in brown adipocyte thermogenesis 
markers 
As noted above (Fig. 2), brown adipose tissue mass was significantly increased in male 
NPYDYNΔ mice. Brown adipose tissue is primarily involved in thermal regulation through its 
mitochondrial abundance of uncoupling protein-1 (UCP-1), the key mediator of brown 
adipocyte thermogenesis through its interactions with free fatty acids to release energy in the 
form of heat, as well as peroxisome proliferator-activated receptor-gamma coactivator 1 alpha 
(PGC1-α), which acts as a cold-inducible protein that controls adaptive thermogenesis 
(Fernandez-Marcos and Auwerx, 2011). To gain insight into whether NPYDYNΔ mice may 
have had altered thermogenesis, which could help to explain their obese phenotype, we 
measured protein levels of these key mediators of thermoregulation in the brown adipose 
tissue of our male mice. Compared to wildtype mice, NPYΔ mice displayed significantly 
elevated UCP-1 protein levels, whereas DYNΔ and NPYDYNΔ mice showed no significant 
difference (Fig. 5A). No differences were seen in PGC1-α protein content in brown adipose 
tissue when comparing any knockout group with that of wildtype mice (Fig. 5B). 
 
 
3.6. Double deletion of both NPY and dynorphin has no effect on glucose metabolism 
As determined by intraperitoneal glucose tolerance tests and the resultant curves of serum 
glucose concentrations, and as compared to wildtype controls, double deletion of NPY and 
dynorphin precursors had no effect on glucose metabolism in male or female mice (Fig. 6). 
This was despite significant, albeit opposite, differences in these parameters in single 
knockout mice. Indeed, both male and female NPYΔ mice demonstrated worsened glucose 
tolerance relative to wildtype controls, and male but not female DYNΔ had improved glucose 
tolerance (Fig. 6). 
 
4. Discussion 
 
The results from this study demonstrate that the simultaneous ablation of both NPY and 
dynorphin in mice does not induce greater weight or fat losses than changes induced by 
single deletion of either NPY or dynorphin. In fact, double deletion of NPY and dynorphin 
resulted in significantly heavier mice, with corresponding and marked increases in adiposity 
relative to wildtype controls. This was a surprising finding as it has previously been reported, 
and corroborated, although not significantly in both sexes in this particular study cohort, that 
DYNΔ mice actually display an antiobesity effect through decreased visceral and 
subcutaneous adiposity levels (Sainsbury et al., 2007). Moreover, NPY knockout mice have 
previously been shown to exhibit either unchanged food intake (Erickson et al., 1996a and Hill 
and Levine, 2003), as well as unaltered body weight and/or adiposity levels (Erickson et al., 
1996a and Zengin et al., 2013), or in some circumstances, including leptin deficiency 
(Erickson et al., 1996b), reductions in fat mass (Baldock et al., 2009 and Zengin et al., 2013). 
Indeed, in our current cohort of NPY knockout mice we observed no significant change from 
wildtype with respect to body weight or adiposity. Therefore, it can be seen that the obesity-
resistant phenotype of single DYNΔ mice and the unaltered body weight and adiposity of 
NPYΔ mice in this study was not carried over to the double NPYDYNΔ mice, which displayed 
no combinatory or synergistic effect with regards to body weight and composition. 
 The increased body weight and adiposity seen in our NPYDYNΔ mice cannot be 
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explained by consistent increases in energy intake in both sexes, and do not seem to be 
explained by altered thermogenesis, either. NPYDYNΔ mice did not have a clearly altered 
food intake phenotype, when measured either under spontaneous or fasting-induced 
conditions, nor did they exhibit differences from wildtype mice with respect to brown adipose 
tissue content of the major thermogenesis markers, UCP-1 and PGC1-α. Although the weight 
of brown adipose tissue in male NPYDYNΔ mice was significantly increased relative to 
wildtype, this is likely due to an increase in the relative size of the brown adipocytes or 
increased white adipocyte infiltration, as opposed to functional changes in thermogenic 
capacity. Therefore, the markedly obese phenotype of the NPYDYNΔ mice must be due to 
other factors besides altered energy intake or thermogenesis, such as decreases in physical 
activity or energy expenditure, greater propensities to utilise carbohydrates over fats as fuel, 
or by the increased absorption of energy from food by the gastrointestinal tract, as has 
recently been reported in antibiotic-exposed mice that became obese despite no changes in 
food intake or energy expenditure (Cho et al., 2012). Additionally, other changes in body 
composition have been demonstrated in these experimental mouse models. Bone tissue 
makes a substantial contribution to body weight, and in both single NPYΔ and DYNΔ mouse 
models, indices of elevated cancellous bone mass have been reported (Baldock et al., 2012). 
Interestingly, NPYDYNΔ double knockout mice also exhibit a similar increase in bone volume 
to that of single deletion mouse models (Baldock et al., 2012). This demonstrates a 
relationship between dynorphin and NPY in the control of other body composition 
components besides adipose tissue, namely, bone. 
 
 
 
 The greater amount of weight lost after a 24-h fast seen in the female double 
NPYDYNΔ mice, which was not seen in either single NPYΔ or DYNΔ mice, could perhaps 
suggest a synergistic relationship between the two orexigenic pathways of NPY and 
dynorphin. Specifically, an additive regulatory mechanism in protecting against excess loss of 
body weight after food deprivation may be a specific function of these two orexigenic 
pathways, in which other regulatory pathways are not able to compensate for. Similarly, with 
regards to glucose homeostasis, additive effects of both the single NPY and dynorphin 
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ablation appear to occur in the NPYDYNΔ mice. Double NPYDYNΔ mice of either gender do 
not display an altered blood glucose time-course profile after an injection of glucose, 
compared to that of wildtype mice. However, both male and female NPYΔ mice demonstrated 
worsened glucose tolerance, and male but not female DYNΔ had improved glucose 
tolerance. The double NPYDYNΔ mouse model seems to respond in a manner that combines 
the responses of the two single NPYΔ and DYNΔ models, thus negating their opposing 
effects. 
 It is counter-intuitive that double deletion of two systems that have previously been 
implicated in mediating obesogenic responses – the NPY and dynorphin precursors – 
resulted in a markedly obese animal model. It is noteworthy that our studies specifically 
focused on the disruption of dynorphins. Dynorphins activate all three types of opioid 
receptors (µ, δ and κ), but bind with much higher preference for κ-opioid receptors (Hamilton 
and Bozarth, 1988), which have been implicated in the regulation of energy homeostasis 
(Arjune and Bodnar, 1990, Hamilton and Bozarth, 1988 and Levine et al., 1990). It is possible 
that other endogenous opioid system peptides, the endorphins and enkephalins, could 
functionally compensate for the absence of dynorphin function. Additionally, as germline 
knockout models exhibit compensation from other systems (Cooke et al., 1997), a double 
knockout mouse model, where two physiological systems have been disrupted, may 
experience an even stronger compensatory functional response. Indeed, it has been shown 
that simultaneous disruption of both Y1 and Y5 receptors, purported to be ‘feeding receptors’ 
mediating orexigenic effects of NPY, resulted in expectedly decreased food intake, yet these 
animals become obese (Nguyen et al., 2012). Interestingly, this phenomenon was observed 
even when both Y1 and Y5 receptors were deleted in an inducible, adult-onset knockout 
model (Nguyen et al., 2012), demonstrating a fundamental tendency for mammals to become 
obese. These phenomena could provide an explanation for the results seen in the double 
NPYDYNΔ model of this study. To overcome such developmental compensation, 
pharmacological antagonists against both NPY and dynorphin could be tested in obese mice. 
 Pharmaceuticals that target dual systems are the next step in the race to develop 
effective obesity pharmacotherapy. Recently, several fixed-dose combination drugs that 
target dual pathways to treat obesity in a multifaceted, synergistic way have either been 
submitted to the FDA for approval, or are in late phase clinical research and development. 
These drug therapies include Qsymia, developed by Vivus, which is a drug combining 
phentermine, an appetite suppressant and topiramate, an anticonvulsant; Empatic, marketed 
by Orexigen Therapeutics, a combination of bupropion, which disrupts the catecholamine 
system and zonisamide, also an anticonvulsant; as well as Amylin’s Symlin, a synthetic 
analogue of pancreatic peptide combining amylin and metreleptin, a leptin agonist. 
Additionally, the aforementioned Contrave utilises a combination of opioid receptor 
antagonism and dopamine reuptake inhibition, through naltrexone and bupropion 
respectively. In light of our current findings, long-term dual targeting of NPY and dynorphins 
may not be a suitable strategy for the treatment of obesity. 
 In conclusion, it can be seen that combining opioid blockade with disruption of the 
NPY system via genetic ablation did not elicit anti-obese effects in mice, but instead resulted 
in marked obesity. While the targeting of multiple pathways will likely be a major part of the 
development of effective new obesity treatments, and while opioid antagonism has recently 
been increasingly investigated as a potential anti-obesity treatment, combining long-term 
opioid antagonism with long-term NPY-ergic blockade would seem unlikely to produce more 
effective anti-obesity treatments. 
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